Skip to Main Content

Author Details

Lixia Diao
The University of Texas MD Anderson Cancer Center
2003
147
56
PMIDPaper TitleJournal TitlePublished Year
37870463PancanQTLv2.0: a comprehensive resource for expression quantitative trait loci across human cancers.Nucleic Acids Res2024
36787696CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.Cancer Cell2023
37655662Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer.J Clin Invest2023
37449205Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance.Front Immunol2023
34534336GPEdit: the genetic and pharmacogenomic landscape of A-to-I RNA editing in cancers.Nucleic Acids Res2022
35346313Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.J Exp Clin Cancer Res2022
35654454The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8<sup>+</sup> cytotoxic T-cell response.Genes Dev2022
36099885Race is a key determinant of the human intratumor microbiome.Cancer Cell2022
36170810Impad1 and Syt11 work in an epistatic pathway that regulates EMT-mediated vesicular trafficking to drive lung cancer invasion and metastasis.Cell Rep2022
35944232Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set.JCO Clin Cancer Inform2022
35058327Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy.J Immunother Cancer2022
34654720Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado.Mol Cancer Res2022
32577652Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.bioRxiv2021
33686493Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma.Cancer Immunol Immunother2021
33705549Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy.J Natl Cancer Inst2021
34977836Profiling of immune features to predict immunotherapy efficacy.Innovation (Camb)2021
34556188Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer.Cancer Metab2021
34526717Structure-based classification predicts drug response in EGFR-mutant NSCLC.Nature2021
34789716Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer.Nat Commun2021
34732702The EMT activator ZEB1 accelerates endosomal trafficking to establish a polarity axis in lung adenocarcinoma cells.Nat Commun2021
34678153Expression of chimeric antigen receptor therapy targets detected by single-cell sequencing of normal cells may contribute to off-tumor toxicity.Cancer Cell2021
34274504Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology.J Thorac Oncol2021
34295654Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse.Transl Lung Cancer Res2021
34311109Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC.J Thorac Oncol2021
34309585Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer.JCI Insight2021
33972557Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.Nat Commun2021
33172976AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors.Mol Cancer Res2021
33402388Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.Cancer Res2021
33309987Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype.J Thorac Oncol2021
33452456Small non-coding RNAs in human cancer: function, clinical utility, and characterization.Oncogene2021
33416944CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma.Cancer Immunol Immunother2021
33388477Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.J Thorac Oncol2021
33388476Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC.J Thorac Oncol2021
33096269Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC.J Thorac Oncol2021
33482121Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.Cancer Cell2021
33119754HeRA: an atlas of enhancer RNAs across human tissues.Nucleic Acids Res2021
33003194Adverse events associated with potential drugs for COVID-19: a case study from real-world data.Brief Bioinform2021
31432762tRic: a user-friendly data portal to explore the expression landscape of tRNAs in human cancers.RNA Biol2020
33574900Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers.Ecancermedicalscience2020
32068166STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.J Thorac Oncol2020
33225964Characterization of the dual functional effects of heat shock proteins (HSPs) in cancer hallmarks to aid development of HSP inhibitors.Genome Med2020
32576192The genetic and pharmacogenomic landscape of snoRNAs in human cancer.Mol Cancer2020
32908154Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8<sup>+</sup> T cell exhaustion.Nat Commun2020
32878980A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components.Sci Transl Med2020
33009409Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy.Nat Commun2020
32183953Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.Cancer Cell2020
32350118Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort.J Immunother Cancer2020
32294413A Multi-Omics Perspective of Quantitative Trait Loci in Precision Medicine.Trends Genet2020
32286310Sex-associated molecular differences for cancer immunotherapy.Nat Commun2020
31586392APAatlas: decoding alternative polyadenylation across human tissues.Nucleic Acids Res2020
  • 1 - 50 of 147

Recommended Authors

Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 1
Andrew Goodspeed
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 0
Yang Shao
Nanjing Geneseeq Technology Inc.
Career Start Year 2012
Number of shared co-authors 3
Cristina Ivan
The University of Texas MD Anderson Cancer Center
Career Start Year 2010
Number of shared co-authors 24
Larissa A Pikor
Ottawa Hospital Research Institute
Career Start Year 2010
Number of shared co-authors 1
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Chad V Pecot
University of North Carolina at Chapel Hill
Career Start Year 2009
Number of shared co-authors 14
Karolina Edlund
Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund
Career Start Year 2008
Number of shared co-authors 0
Yang Xie
Quantitative Biomedical Research Center
Career Start Year 2007
Number of shared co-authors 12
Pichai Raman
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Career Start Year 2006
Number of shared co-authors 8
Dennis Wang
Sheffield Institute of Translational Neuroscience, University of Sheffield
Career Start Year 2006
Number of shared co-authors 0
Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 2
Andrew V Kossenkov
The Wistar Institute
Career Start Year 2003
Number of shared co-authors 3
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 15
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 4
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 2
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 40
Habib Hamidi
Genentech Inc.
Career Start Year 2002
Number of shared co-authors 0
Ludmila Danilova
Bloomberg-Kimmel Immunotherapy Institute, Johns Hopkins University School of Medicine
Career Start Year 2001
Number of shared co-authors 30
Wenyan Zhong
Oncology R&D
Career Start Year 2000
Number of shared co-authors 1
Loris De Cecco
Fondazione IRCCS Istituto Nazionale dei Tumori
Career Start Year 2000
Number of shared co-authors 2
Collin M Blakely
University of California san francisco
Career Start Year 1998
Number of shared co-authors 8
Lianbo Yu
The Ohio State University
Career Start Year 1997
Number of shared co-authors 2
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 23
Patrick Micke
Uppsala University
Career Start Year 1997
Number of shared co-authors 0
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 1
Woong-Yang Park
Samsung Genome Institute, Samsung Medical Center
Career Start Year 1995
Number of shared co-authors 12
Timothy A Chan
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 33
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 5
Matthew Meyerson
Broad Institute
Career Start Year 1983
Number of shared co-authors 62

Collaborators

John D Minna
University of Texas Southwestern Medical Center at Dallas
Co-authored papers 22
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 22
Zhao Zhang
Co-authored papers 20
Youqiong Ye
Co-authored papers 19
Jianjun Zhang
The University of Texas MD Anderson Cancer Center
Co-authored papers 14
Kevin R Coombes
Medical College of Georgia
Co-authored papers 14
John N Weinstein
The University of Texas MD Anderson Cancer Center
Co-authored papers 11
Han Liang
MD Anderson Cancer Center
Co-authored papers 8
Roy S Herbst
Yale School of Medicine
Co-authored papers 8
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Co-authored papers 7
Steven H Lin
University of Texas MD Anderson Cancer Center
Co-authored papers 7
Laura A Gibson
The University of Texas MD Anderson Cancer Center
Co-authored papers 6
Chad J Creighton
Co-authored papers 6
Scott M Lippman
Moores Cancer Center, university of california san diego
Co-authored papers 6
Keith A Baggerly
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Yiling Lu
Co-authored papers 5
Vincent A Miller
Injury Prevention Research Center, University of North Carolina
Co-authored papers 5
Rehan Akbani
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Yuan Yuan
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Zhenlin Ju
Co-authored papers 4
Michael Peyton
Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center
Co-authored papers 4
Daniel J McGrail
Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Co-authored papers 4
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Co-authored papers 4
Daniel R Gomez
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Huandong Sun
Co-authored papers 4
Wenbin Liu
Co-authored papers 3
Roel G W Verhaak
Yale School of Medicine
Co-authored papers 3
Timothy P Heffernan
Co-authored papers 3
Naoto T Ueno
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Co-authored papers 3
Release 1.2